Exchange
BME
Every company in the roster listed on BME.
Research
Compare financial metrics on this exchange
Research adds market cap, cash, runway and annualized R&D metrics with metric-specific sorting.
Views
4 of 4 companies
| Company | Pipeline | Most advanced | Next readout |
|---|---|---|---|
 GrifolsGRF · BME | 2 assets: 1 Ph 3, 1 Ph 2 | Human hepatitis B Immunoglobulin (Hepatect®CP/Zutectra®)Phase 3 · Chronic Hepatitis B | None on record |
 Laboratorios Farmacéuticos Rovi, S.A.ROVI · BME | 2 assets: 1 approved, 1 Ph 3 | Risperidone (QUAR)Phase 3 · SchizophreniaWeak signal | None on record |
 PharmaMarPHM · BME | 2 assets: 1 approved, 1 Ph 3 | PlitidepsinPhase 3 · Multiple MyelomaPartial signal | 28 Jan 2028Lurbinectedin · Phase 1/2 |
 Oryzon Genomics, S.A.ORY · BME | 1 asset: 1 Ph 2 | IadademstatPhase 2 · Acute Myeloid LeukemiaWeak signal | None on record |
Next readout: the earliest estimated primary completion of a trial the company or a partner on the asset runs (ClinicalTrials.gov).